Kewalramani Reshma 4

What Happened Reshma Kewalramani, CEO & President and a director of Vertex Pharmaceuticals (VRTX), surrendered 13,041 shares on Feb 13, 2026 to satisfy tax liabilities related to an equity award/option event. The shares are reported as disposed at $487.76 per share, totaling approximately $6,360,878. This transaction is a tax withholding/net-share settlement (not an open-market sale).

Key Details

• Transaction date: 2026-02-13; Filing date: 2026-02-18 (filed within the SEC two-business-day window).
• Shares surrendered/disposed: 13,041 at $487.76 per share; aggregate value ≈ $6,360,878.
• Transaction code: F — payment of exercise price or tax liability (shares were withheld to cover taxes).
• Shares owned after transaction: not specified in the provided filing excerpt.
• This was a withholding/net settlement to meet tax obligations, not a public sale or purchase.

Context Code F transactions commonly occur when restricted stock units vest or options are exercised and the company withholds shares to cover taxes. Such withholdings are administrative and do not necessarily indicate the insider's view on the company's stock.